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Dopaminergic involvement in 
activational aspects of motivation
Similar to other psychological constructs such as 
emotion and cognition, motivation is not a simple 
or unitary phenomenon. Motivation is a com-
plex and multifacted process that includes many 
diverse components. Some aspects of motivation 
are related to sensations of internal and external 
stimuli, while other aspects of motivation are 
related to motor function [1]. Motivated behav-
ior takes place in phases that represent different 
degrees of physical or psychological distance from 
the primary motivational stimulus (i.e., appeti-
tive vs consummatory; instrumental vs consum-
matory; see [2–4]). Moreover, motivation theory 
and research has emphasized for several years that 
there are ‘directional’ and ‘activational’ aspects 
of motivation [5–7]. Directional aspects refer to 
the observation that the behavior of animals is 
directed towards or away from particular moti-
vational stimuli. In addition, it is evident that 
motivated behavior can be characterized by per-
sistence, vigor and high levels of work output; 
these activational aspects of motivated behavior 
are highly adaptive because they enable organ-
isms to overcome challenges or work-related 
response costs that separate them from signifi-
cant stimuli such as food [4,8–13]. While foraging 
in the wild, animals can invest considerable time 
and can cover large areas of space in order to 
gain access to food or other primary motivational 
stimuli. Laboratory experiments have shown that 
animals can climb barriers, run in mazes or press 
levers on schedules with high input ratio require-
ments, in order to gain access to motivational 
stimuli such as food. Under some conditions the 
presentation of motivational stimuli can generate 
heightened, even excessive, levels of motor activ-
ity. In humans, impairments in behavioral acti-
vation can manifest themselves as energy-related 
symptoms such as psychomotor slowing, aner-
gia and fatigue, which are features of depression, 
and can also be observed in other psychiatric or 
n eurological disorders [11]. 
In addition to studying these behavioral proc-
esses involved in activational aspects of motiva-
tion, neuroscientists have also focused upon the 
brain mechanisms that are potentially involved. 
Several brain areas have been investigated, but 
one of the neural systems most closely associ-
ated with behavioral activation is the dopamine 
(DA) innervation of the nucleus accumbens 
[8–11,14,15]. Although the mesolimbic DA sys-
tem has consistently been linked to aspects of 
drug reinforcement, and is often referred to as 
some type of ‘pleasure’ or ‘reward’ center, recent 
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research has demonstrated that the story is much 
more complicated and there are signs of a ‘para-
digm shift’ taking place in this field [11,16]. In 
fact, neither DA antagonists, whole forebrain 
DA depletions or localized DA depletions in 
nucleus accumbens affect appetitive taste reac-
tivity for food [17–20]; these findings have con-
sistently been interpreted to suggest that inter-
ference with mesolimbic DA transmission does 
not blunt the hedonic reaction to food (i.e., ‘lik-
ing’). Although Gunne and colleagues reported 
that the hedonic effects of amphetamine could 
be blocked by DA D2 receptor antagonism [21], 
considerable research has failed to support this 
hypothesis [22–24]. The D1 antagonist ecopipam 
did not blunt either the self-administration or 
the subjective pleasure induced by cocaine [25,26]. 
In addition, catecholamine depletion induced 
by feeding indivi duals a phenylalanine/tyrosine-
free diet did not reduce cocaine-induced hedo-
nia or self-administration [27]. In this context, 
it is worth noting that substantial literature has 
linked nucleus accumbens in general, and its DA 
innervation in particular, to aspects of aversive 
learning, aversive motivation and stress [28–44]. 
It is generally recog nized that whole forebrain 
DA depletions can produce aphagia (i.e., lack 
of eating); however, in animals, this effect has 
been conclusively linked to motor or sensorimo-
tor impairments induced by depletions of DA 
in the lateral or ventrolateral caudate/putamen, 
but not to actions upon the nucleus accumbens 
[44–47]. Several papers have shown that nucleus 
accumbens DA depletions do not substantially 
impair appetite for food, or produce a broad dis-
ruption of directional aspects of primary food 
motivation [46–48]. Depletions of DA in nucleus 
accumbens failed to reduce food intake or feed-
ing rate, and did not impair food handling, 
although similar depletions in the ventro lateral 
neostriatum did affect these measures of feed-
ing [46]. DA D1 or D2 family antagonists injected 
into either the core or the shell subregions of 
nucleus accumbens impaired locomotion and 
rearing, but did not suppress food intake, which 
led Baldo et al. to conclude that DA receptor 
antagonism “did not abolish the primary moti-
vation to eat” [49]. Several studies have demon-
strated that nucleus accumbens DA depletions, 
as well as systemic or intra-accumbens DA 
antagonism, do not produce effects that closely 
resemble those resulting from motivational 
manipulations, such as prefeeding or appetite 
suppressant drugs [50–54]. Thus, despite claims 
to the contrary, nucleus accumbens DA has not 
been strongly implicated in food consumption, 
appetite or primary food motivation [13]. Similar 
arguments have been made with regard to other 
motivational conditions, including sexual and 
maternal behaviors [55–58].
By contrast, an enormous body of evidence 
demonstrates that nucleus accumbens DA is 
involved generally in behavioral activation and, 
more specifically, in effort-related aspects of 
food motivation. Accumbens DA depletions 
reduced spontaneous and novelty-induced 
locomotor activity and rearing, as well as stim-
ulant-induced activity [48,59,60]. Behaviors such 
as excessive drinking, wheel-running or loco-
motor activity, which are induced by scheduled 
presentation of food pellets to food-deprived 
animals, were reduced by accumbens DA deple-
tions [61–63]. Furthermore, the effects of nucleus 
accumbens DA depletions on food-reinforced 
instrumental behavior depend greatly upon the 
specific task requirements of the schedule of 
food reinforcement. Schedules with minimal 
work requirements, such as a fixed ratio (FR) 1, 
and variable interval (VI) or progressive inter-
val schedules, are relatively insensitive to the 
effects of accumbens DA depletions [59,64–72]. 
In fact, one of the critical factors that makes 
a food-reinforced operant task sensitive to the 
effects of accumbens DA depletions is the size of 
the ratio requirement (i.e., the number of times 
they have to press the lever to receive food); as 
ratio requirements get higher, rats become more 
sensitive to the response-suppressing effects of 
accumbens DA depletions [66–68,70–72]. The 
impact of ratio requirement as a factor that 
leads to increased sensitivity to the effects of 
accumbens DA depletions is not simply depend-
ent upon the degree of intermittence in the 
schedule (i.e., the time spent with no primary 
reinforcers). While performance on VI 30, 60 
or 120 s schedules was minimally affected by 
accumbens DA depletions, attachment of a ratio 
requirement (FR5 or 10) to the interval require-
ment made these schedules highly sensitive to 
the response-suppressing effects of accumbens 
DA depletions [59,68]. Together with studies of 
food intake, this pattern of results indicates that 
nucleus accumbens DA depletions leave funda-
mental aspects of appetite or primary food moti-
vation intact, but reduce the tendency of the 
animals to work for food reinforcement.
Accumbens dopamine & effort-related 
decision making
In a complex environment there may be several 
motivational stimuli available concurrently (e.g., 
different types of food), which can vary in terms 
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of quantity or quality. Typically, there would also 
be diverse patterns of instrumental behavior that 
are necessary for obtaining access to each stim-
ulus, with response requirements that vary in 
terms of time, work and other parameters. Thus, 
in order to adapt to these conditions, organisms 
must select between various alternatives, making 
effort-related decisions and allocating behavioral 
resources based upon numerous factors related to 
response cost and reinforcement value. In addi-
tion to being involved in the exertion of effort, 
nucleus accumbens DA also participates in the 
process of effort-related choice behavior. 
A number of behavioral procedures have been 
developed that allow for the assessment of how 
animals allocate resources based upon analyses 
of reinforcement value and response cost. For 
example, a T-maze procedure was developed to 
assess the effects of accumbens DA depletions on 
response choice based upon task difficulty [73]. 
The two choice arms of the maze can have differ-
ent reinforcement densities (e.g., four vs two food 
pellets, or four vs zero), and in order to provide 
an effort-related challenge, a 44-cm barrier can 
be placed in the arm with the higher density of 
food reinforcement (FIGURE 1). When no barrier is 
present in the arm with the high reinforcement 
density, rats strongly prefer that arm, and neither 
haloperidol nor accumbens DA depletion alters 
their response choice [73]. When the arm with 
the barrier contained four food pellets, but the 
other arm contained no pellets, so that the only 
way to obtain food was by climbing the barrier, 
rats with accumbens DA depletions still chose the 
high-density arm, climbed the barrier and con-
sumed the pellets [74]. These control experiments 
indicated that interference with DA transmission 
did not impair memory for which arm had the 
most pellets, did not affect the discrimination 
of reinforcement density and did not alter arm 
preference. Nevertheless, low doses of DA antago-
nists and accumbens DA depletions dramatically 
altered choice behavior when the high-density arm 
(four pellets) had the barrier in place, and the arm 
without the barrier contained an alternative food 
source (two pellets). Under these conditions, rats 
with impaired DA transmission showed decreased 
choice for the high-density arm that contained 
the barrier, and increased choice for the arm with 
less food that did not have a barrier [73–75]. More 
recently, a mouse version of the T-maze task has 
been developed [76]. As with rats, the DA antago-
nist haloperidol decreased selection of the arm 
with the barrier in mice, but increased selection of 
the arm with no barrier, which contained a lower 
density of food reward. Interestingly, the same 
doses of haloperidol had no effect on choice when 
both arms were blocked by barriers; this observa-
tion confirms that the haloperidol-treated mice 
were capable of climbing the barrier, and remem-
bered which arm had the higher density of reward, 
but these mice chose not to climb the barrier when 
there was an alternative food source available that 
could be reached with less effort. Taken together, 
these experiments indicate that accumbens DA 
depletions cause animals to re allocate their 
instrumental responses based upon the response 
r equirements of the task (reviewed in [8–11,77]).
Another task that has been developed is an 
operant concurrent choice procedure that offers 
rats a choice between lever pressing to obtain a 
preferred food (high carbohydrate pellets), ver-
sus approaching and consuming a less preferred 
food (laboratory chow) that is concurrently avail-
able. Under baseline or control conditions, rats 
responding on FR1 or FR5 schedules typically 
get most of their food by lever pressing, and they 
eat minimal quantities of chow. However, low-
to-moderate doses of DA antagonists with vary-
ing degrees of selectivity produce a substantial 
alteration of response allocation. The DA antag-
onists cis-flupenthixol, haloperidol, raclopride, 
eticloprided, SCH 23390, SKF83566 and eco-
pipam (SCH 39166) all decreased lever pressing 
for food but substantially increased intake of the 
concurrently available chow [51,53,54,77,78]. By con-
trast, knockdown of the DA transporter in mice 
resulted in the opposite effect; that is, increases in 
lever pressing and decreases in chow intake [79]. 
The nucleus accumbens, rather than the neo-
striatum, is the DA terminal region most closely 
associated with the effects of DA depletion or 
antagonism. Ventrolateral neostriatal DA deple-
tions produced severe motor impairments that 
merely decreased both types of behavior, while 
injections of 6-hydroxydopamine into the antero-
ventromedial neostriatum were ineffective [80]. 
Decreases in lever pressing and increases in chow 
intake were produced by accumbens DA deple-
tions, as well as by intra-accumbens injections of 
D1 or D2 family antagonists [51,66,80–84]. The shift 
from lever pressing to chow intake on this task 
has been demonstrated to occur if injections of 
D1 or D2 family antagonists were administered 
into the medial core, lateral core or dorsome-
dial shell subregions of the accumbens [51,82–84]. 
Although injections of the D2 antagonist, eti-
clopride, into nucleus accumbens core shifted 
behavior from lever pressing to chow intake, 
injections into a dorsomedial neostriatal control 
site were ineffective [84]. Thus, despite the fact 
that lever pressing is decreased by accumbens 
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DA antagonism or depletions, the rats show a 
compensatory reallocation of behavior and select 
a new path to an alternative food source. 
Several control experiments have been con-
ducted in order to characterize the significance of 
these effects with dopaminergic manipulations. 
For example, behavioral experiments demon-
strated that the concurrent choice task is sensi-
tive to both the type of food being offered [85] 
and the work requirement of the lever press-
ing task [8]. Other studies have indicated that 
interference with accumbens DA transmission 
does not appear to produce a severe impairment 
in motor capacity. Injections of DA D1 or D2 
family antagonists into the nucleus accumbens 
core and shell that produced the shift from lever 
pressing to chow intake did not increase lever 
press response duration [83], which indicates 
that these manipulations were not producing 
catalepsy (for a discussion of response duration, 
see [86]). These observations are consistent with 
a report showing that rats with mild accumbens 
DA depletions could still demonstrate the shift 
from FR5 lever pressing to chow intake even 
when separate tests demonstrated that there 
was no significant impairment in responding 
when the FR5 schedule was available without 
food being present [81]. Parallel studies with 
free-feeding choice tests indicated that prefer-
ence for the pellets over the laboratory chow, as 
well as food intake, were not affected by the vari-
ous conditions that produce the shift from lever 
pressing to chow intake; this includes adminis-
tration of low doses of haloperidol [51], as well as 
intra-accumbens injections of sulpiride or SCH 
23390 [82]. With rats performing on the con-
current choice task, prefeeding to reduce food 
motivation was demonstrated to suppress both 
lever pressing and chow intake [51]. Although DA 
antagonists have been shown to reduce FR 5 lever 
pressing and increase chow intake, appetite sup-
pressants such as fenfluramine and cannabinoid 
CB1 antagonists showed a very different pattern 
of effects [53,54], and did not increase chow intake 
at doses that suppress lever pressing. Together 
with the other results (reviewed previously), 
these findings demon strate that interference 
with DA t ransmission does not simply reduce 
appetite for food.
In summary, animals administered low doses 
of DA antagonists, or those with accumbens DA 
depletions, remain directed towards the acquisi-
tion and consumption of food. Furthermore, 
they do not show severe impairments in motor 
capacity. Nevertheless, they manifest a reduced 
tendency to work for food, and their choice 
behavior is altered such that they become biased 
towards obtaining food through responses that 
have lower work-related costs. Thus, rats with 
impaired accumbens DA transmission switch 
from lever pressing for preferred food pellets to 
approaching and consuming the less preferred 
chow, and they switch from climbing the barrier 
to obtain the higher density of food reinforce-
ment towards the alternative arm of the maze, 
which has less food that can be obtained with 
a lower degree of effort. The results of these 
studies are consistent with recent papers demon-
strating that DA antagonists also affect effort 
discounting [87,88]. Bardgett et al. developed 
an effort-discounting version of the T-maze 
task [88], in which the amount of food in the 
high-density arm of the maze was diminished 
every time the rats selected that arm. Their 
results demonstrated that both the D1 family 
antagonist SCH23390 and the D2 family antag-
onist haloperidol altered effort discounting, 
making it more likely that rats would choose 
the arm with the smaller reward. Moreover, 
they observed that amphetamine produced 
the opposite effect, making it easier for rats 
to tolerate greater exertion of effort. Floresco 
et al. reported that haloperidol affected effort 
discounting even when one controlled for any 
Figure 1. Top view of the T-maze apparatus used in the Mott et al. 2009 
study. The start arm of the maze consisted of an enclosed plexiglas box (29 × 21 × 
21 cm) with a wire mesh floor grid. The test arm of each side of the maze was a 
box 99 × 32 × 59 cm. The test arm and back walls of the maze were constructed 
out of Plexiglas®, and the floor was wire mesh. The doorway from the start arm to 
the maze was a stainless steel guillotine door. The barrier (depicted in the high-
density arm, to the left) was constructed of wire mesh (44 × 32 cm). The high-
density arm contained four food pellets, and the low-density arm contained two 
food pellets. 
Taken from [75].
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possible time delays caused by completing the 
ratio [87]. Taken together, these results indicate 
that DA systems participate in the regulation of 
effort-based decision making.
Forebrain circuits & neurotransmitter 
interactions regulating  
effort-related processes
Although interference with accumbens DA 
transmission can exert profound effects on some 
aspects of motivation, these effects do not appear 
to be a result of actions such as appetite sup-
pression or reductions in the primary or uncon-
ditioned motivation for food [8,11,15,49,77,89]. 
Instead, considerable evidence indicates that 
DA antagonists and accumbens DA depletions 
alter functions such as behavioral activation, 
instrumental response output and allocation, 
and effort-related processes [8,11,14,15,49,77,87–92]. 
Of course, accumbens DA does not regulate 
effort-related processes in isolation, and for 
that reason it is important to review how other 
brain areas and neurotransmitters are involved. 
Several recent studies have shown that anterior 
cingulate cortex, basolateral amygdala and ven-
tral pallidum also participate in effort-related 
processes [93–97]. The T-maze task previously 
described [73] has been employed to investigate 
the functions of frontal/cingulate cortical areas 
in addition to the accumbens. Walton et al. stud-
ied the effects of medial frontal cortex lesions 
that included prelimbic, infralimbic and anterior 
cingulate cortex, and demonstrated that these 
lesions shifted the behavior of the rats away from 
the arm that contained the high density of rein-
forcement that was obstructed by a barrier  [94]. 
In a subsequent paper, lesions of the prelimbic 
and infralimbic cortex did not affect choice 
behavior, but lesions of the anterior cingulate 
cortex produced the same changes in effort-
related choice that had been shown previously 
with the larger lesions [95]. Large anterior cin-
gulate catecholamine depletions were shown to 
affect T-maze choice behavior [96]. Furthermore, 
bilateral inactivation of anterior cingulate cortex 
also shifted choice behavior in the T-maze [97].
Recent research in this area has also focused 
on interactions between DA and the purine 
neuromodulator, adenosine. Four G-protein-
coupled adenosine receptors have been identi-
fied, although the A1 and A2A subtypes predomi-
nate in the brain [98]. It has been known for some 
time that nonselective adenosine antagonists, 
such as caffeine and theophylline, act as minor 
stimulants [99]. Over the last two decades, there 
has been a tremendous growth in research on 
adenosine receptor neurochemistry and pharma-
cology, and the A2A receptor subtype has received 
considerable attention. Both caudate/putamen 
(neostriatum) and nucleus accumbens are very 
rich in adenosine A2A receptors [100–103]. There is 
a neurochemical interaction between striatal DA 
D2 and adenosine A2A receptors, which tend to 
be colocalized on the same enkephalin-positive 
medium spiny neurons [102–108]. The behavioral 
significance of this interaction has frequently 
been studied in the context of neostriatal motor 
functions and dysfunctions that are related to 
parkinsonism [104,105,109–116]. Investigators have 
also studied adenosine A2A receptor pharma-
cology in relation to cognitive processes [117] and 
anxiety [118]. Within the last few years, the moti-
vational significance of adenosine A2A receptor 
pharmacology has become apparent, especially 
with regard to aspects of behavioral activation 
and effort-related processes [84,119–121].
Broadly speaking, injections of the adeno-
sine A2A agonist, CGS 21680, directly into 
nucleus accumbens have been shown to pro-
duce effects that resemble those of accumbens 
DA depletions or antagonism. Intra-accumbens 
injections of CGS 21680 reduced locomotor 
activity [122]. More recently, it was demonstrated 
that local injection of CGS 21680 into nucleus 
accumbens core reduced response on a VI 60 s 
schedule with an attached FR10 requirement 
attached, but did not impair performance on a 
standard VI 60 s schedule [121], an effect that has 
been shown to occur following accumbens DA 
depletions [68]. In rats responding to the operant 
FR5/chow feeding concurrent choice procedure, 
injections of CGS 21680 into the accumbens 
core decreased lever pressing and increased chow 
intake [120], a pattern of effects similar to that 
produced by accumbens DA depletions and 
antagonism. Injections of CGS 21680 into a 
control site dorsal to nucleus accumbens were 
ineffective [120]. 
Consistent with the observation that an adeno-
sine A2A agonist could produce actions similar to 
those resulting from interference with DA trans-
mission, it has also been demonstrated that ade-
nosine A2A receptor antagonists can reverse the 
effects of DA antagonists on effort-related choice 
behavior. Studies employing the T-maze barrier 
choice procedure demonstrated that the adenos-
ine A2A receptor antagonist, MSX-3, could reverse 
the effects of the D2 antagonist haloperidol in 
both rats [75] and mice [76]. MSX-3 also reversed 
the effects of the D2 antagonists haloperidol and 
eticlopride in rats responding on the concurrent 
lever pressing/chow feeding procedure [79,84,119]. 
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Similar effects have been produced by another 
adenosine A2A receptor antagonist, istradefylline 
(KW 6002; [78, Nunes EJ, Randall PA, Santerre  JL 
et al., Unpublished Data]). These pharmacologi-
cal studies indicate that there is a very specific 
interaction between DA D2 and adenosine A2A 
receptor subtypes. Although the adenosine 
A2A receptor antagonist MSX-3 can reduce the 
effect of haloperidol in rats and mice respond-
ing on the T-maze task, the A1 antagonists, 
8-cyclopentyl-1,3-dipropylxanthine (DPCPX) 
and 8-cyclopentyltheophylline (CPT) were inef-
fective [75,76]. Similarly, DPCPX and CPT were 
unable to reverse the effects of haloperidol and 
eticlopride in rats responding on the operant 
concurrent choice task [78, Nunes EJ, Randall PA, 
Santerre JL et al., Unpublished Data]. Despite the fact 
that both MSX-3 and istradefylline could reverse 
the effects of D2 antagonists, such as haloperi-
dol and eticlopride, in rats responding on the 
operant concurrent choice procedure [78,119,123], 
these drugs produced only a mild attenuation 
the effects of the D1 antagonists ecopipam (SCH 
39166) and SCH 23390 [123, Nunes EJ, Randall PA, 
Santerre JL et al., Unpublished Data]. Furthermore, 
the adenosine A1 antagonists DPCPX and CPT 
were unable to reverse the effects of the DA 
D1 antagonist ecopipam [Nunes EJ, Randall PA, 
Santerre JL et al., Unpublished Data]. Similar results 
were obtained with rats tested on a novelty-
induced locomotion procedure [124]. 
These findings indicate that there is a relatively 
selective interaction between antagonists of DA 
D2 and adenosine A2A receptors (FIGURE 2). Recently, 
it was demonstrated that either systemic or 
intra-accumbens injections of the adenosine A2A 
receptor antagonist MSX-3 reversed the effects of 
intra-accumbens injections of the D2 antagonist 
eticlopride on effort-related choice [84], demon-
strating that nucleus accumbens is an important 
locus for this D2–A2A interaction. Moreover, 
these results from studies of effort-related choice 
behavior are consistent with the large body of 
evidence demonstrating that A2A antagonism 
can generally reverse the effects of D2 antago-
nism across a wide range of behavioral contexts, 
including tasks that involve functions related to 
ventral and dorsal striatum [115,116,124,125]. The 
specificity of this interaction is possibly related 
to the pattern of cellular localization of adeno-
sine A1 and A2A receptors in striatal areas, includ-
ing the nucleus accumbens [103]. Adenosine A2A 
receptors are located on enkephalin-positive 
striatal neurons that also express DA D2 recep-
tors [98,100,103,106,126]. DA D2 and adenosine A2A 
receptors are able to form heteromeric complexes, 
in which the two receptors become linked and 
display alterations in their binding characteris-
tics, and these receptors also converge onto the 
same cAMP-related signal transduction path-
ways [103–105,107,108,127–129]. Thus, adenosine A2A 
antagonists may be so effective at reversing the 
actions produced by DA D2 antagonists because 
they reverse the basic cellular manifestations of 
D2 blockade. Consistent with this hypothesis, 
recent studies have employed c-Fos immunoreac-
tivity to provide a cellular marker of the interac-
tion between DA D2 and adenosine A2A recep-
tors. These experiments have demonstrated that 
doses of adenosine A2A antagonists that are effec-
tive at reversing the actions of DA D2 antagonists 
on tremor and effort-related choice behavior can 
also reverse the D2-antagonist-induced enhance-
ment of c-Fos expression in ventrolateral neo-
striatum [130] and nucleus accumbens core [84], 
respectively. However, despite the colocaliza-
tion of DA D1 and adenosine A1 receptors on 
Figure 2. Summary of drug reversal studies with the operant concurrent 
choice task. This chart lists the effect sizes (R2 values) that provide a marker of the 
magnitude of the reversal effect of each adenosine antagonist when coadministered 
with a DA antagonist. These calculations were performed on the lever pressing data 
from published papers [78], as well as unpublished data [Nunes EJ, Randall PA, 
Santerre JL et al., Unpublished Data]. These analyses were conducted by removing the 
vehicle plus vehicle control data, and calculating the R2 value for the four treatments 
that included a DA antagonist injection alone as well as the DA antagonist 
combined with an adenosine antagonist. With this type of calculation, the 
magnitude of the treatment effect is independent of the number of animals, and is 
expressed as the proportion of total variance accounted for by treatment variance 
(e.g., R2 = 0.3 reflects 30% of the variance explained across experiments and 
measures; larger effect sizes mean greater reversal effects).
CPT: 8-cyclopentyltheophylline; DA: Dopamine;  
DCPCX: 8-cyclopentyl-1,3-dipropylxanthine.
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the same striatal neurons [103], injections of the 
A1 antagonists DPCPX and CPT failed to reverse 
the behavioral effects of the DA D1 antagonist 
ecopipam [Nunes EJ, Randall PA, Santerre JL et al., 
Unpublished Data]. 
In summary, research over the last few years 
has begun to identify components of the brain 
circuitry involved in effort-related processes. 
Nucleus accumbens DA and adenosine interact 
to regulate effort-related choice behavior, and 
other structures, such as basolateral amygdala 
and prefrontal/anterior cingulate cortex, are 
also involved. FIGURE 3 provides an outline of the 
forebrain circuits that participate in effort-related 
functions. Recent research employing a combina-
tion of behavioral, anatomical, neurochemical 
and pharmacological methods has contributed 
to our understanding of the interactions that 
occur between different components of this cir-
cuitry. Using ‘disconnection’ methods, Floresco 
and Ghods-Sharifi demonstrated that unilateral 
inactiva tion of the basolateral amygdala on one 
side of the brain, combined with contralateral 
inactivation of the anterior cingulate cortex, 
substantially altered performance on the T-maze 
barrier choice task [97]. These findings support 
the hypothesis that serial transfer of information 
between these structures is involved in effort-
related decision making. A similar conclusion 
was reached by Hauber and Sommer [131], who 
reported that unilateral cell body lesions of ante-
rior cingulate cortex combined with contralat-
eral cell body lesions of nucleus accumbens can 
also change effort-based decision making in rats 
responding on the T-maze task. Another part of 
this circuitry appears to be the ventral striatopall-
idal pathway. Neurons originating in nucleus 
accumbens core areas that have been implicated 
in effort-related processes project to the lateral 
ventral pallidum [121,132]. The cell bodies of many 
of these neurons also contain adenosine A2A 
receptors [121]. This projection is GABAergic, and 
recent evidence indicates that extracellular levels 
of GABA, as measured by microdialysis, were 
increased by local accumbens core injections of 
either the adenosine A2A agonist CGS 21680 [121] 
or the DA D2 antagonist eticlopride (FIGURE 4) at 
doses that also produce the shift from lever press-
ing to chow intake in rats responding on the 
operant concurrent choice task. Consistent with 
this observation, it was reported that injections of 
the GABAA agonist, muscimol, directly into the 
ventral pallidum also decreased lever pressing and 
increased chow intake [132], while injections of 
muscimol into a control site dorsal to the ventral 
pallidum were ineffective. Moreover, injections 
of the adenosine A2A agonist CGS 21680 into 
nucleus accumbens on one side of the brain, com-
bined with muscimol injected into the ventral 
pallidum on the contralateral side, reduced lever 
pressing in rats responding on a VI 60 s schedule 
that had an additional work requirement (FR10) 
attached [121]. This effect is very similar to that 
previously reported to occur after accumbens DA 
depletions [68].
Clinical significance
In addition to contributing to the basic scientific 
understanding of brain mechanisms related to 
aspects of motivation, studies of effort-related 
processes also have substantial clinical impli-
cations. In her book Manic, Cheney describes 
her own subjective experience of mania in the 
following terms: “increased energy: during 
Figure 3. Forebrain circuits involved in effort-related functions.
Top: Anatomical circuit diagram showing the connections between nucleus 
accumbens and other brain interconnected brain areas (frontal/cingulated cortex, 
amygdala and pallidal areas) that are involved in the regulation of behavioral 
activation and effort-related decision making. Lower right (see arrow): enhanced 
view of nucleus accumbens showing localization patterns for dopamine and 
adenosine receptors.
EPN: Entopeduncular nucleus; mGP: Medial globus pallidus; S. nigra: Substantia 
nigra; VTA: Ventral tegmental area.
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manic episodes, I can zip through all the work 
I couldn’t touch while I was depressed” [133]. 
Although depression is defined as an affec-
tive disorder, with symptoms that include 
mood alterations and negative affect, some 
of the most common symptoms of depression 
are energy-related dysfunctions such as slow-
ness, tiredness, listlessness and apathy [134,135]. 
Sometimes referred to as psychomotor slowing 
or retardation, anergia or fatigue, this cluster 
of symptoms can be a debilitating feature of 
major depressive disorder, and can also be 
present in other psychiatric and neurological 
conditions [134–157]. 
The neural basis of the impaired psychomotor 
function presented in major depressive disorder 
is still being characterized. Nevertheless, con-
siderable evidence implicates central DA, basal 
ganglia and cortical mechanisms [11,140–145]. 
Caligiuri and Ellwanger suggested that DA 
transmission could play an important role in the 
expression of psychomotor slowing in depres-
sion [142]. Schmidt et al. observed that reduced 
DA transmission in psychiatric patients was not 
related to anhedonia, but instead was related 
to decreased interaction with the environment 
and psychomotor slowing [144]. The efficacy 
of several antidepressant drugs for reversing 
psycho motor slowing in depressed patients was 
related to the ability of these drugs to inhibit 
DA uptake [145]. Stimulants that enhance 
DA transmission have also been used to treat 
energy-related symptoms in depressed indi-
viduals [136]. Antiparkinsonian drugs such as 
l-DOPA and bromocriptine have mixed anti-
depressant charac teristics with regard to other 
symptoms of depression, but they do tend to 
improve anergia [141]. Imaging studies also 
have implicated the basal ganglia structures, 
as well as interconnected brain areas such as 
prefrontal cortex and anterior cingulate cortex, 
in p sychomotor slowing in depression [146,147].
In addition to being a feature of major depres-
sive disorder, energy-related dysfunctions are 
often observed in patients with other psychi-
atric or neurological conditions. Moreover, as 
is the case with major depression, the anergia, 
apathy and fatigue observed in these patients 
appears to involve DA systems and basal gan-
glia mechanisms. There are several reports 
of energy-related problems, typically labeled 
fatigue, in patients with Parkinson’s dis-
ease [152]. These patients describe their loss of 
energy by statements such as “my energy bub-
ble just bursts” and “it’s like my battery runs 
down” [152]. Caligiuri and Ellwanger compared 
Figure 4. D2 blockade in nucleus accumbens increases GABA release in 
ventral pallidum. (A) Diagram showing the placement of a drug injection cannula 
in nucleus accumbens, and a microdialysis probe in the ipsilateral ventral pallidum. 
For these studies [Farrar, unpublished doctoral dissertation, University of 
Connecticut, 2009], either 4.0 µg of the D2 antagonist eticlopride (n = 7) or saline 
vehicle (n = 8) was injected into the nucleus accumbens core (1.0 µl total volume). 
The dialysis samples obtained from ventral pallidum were collected over successive 
30-min periods and were analyzed using high-performance liquid chromatography 
with electrochemical detection. These microdialysis and neurochemical methods 
have been published previously [124]. Rat brain coronal sections were modified 
from [133]. (B) Graph showing the effect of eticlopride injection on extracellular 
GABA, with data expressed as a percentage of baseline. This graph includes data 
(mean + standard error of the mean) from the last two baseline preinjection 
samples (BL1–2), and the five samples after injection, for groups treated with 
eticlopride or vehicle (D1–5; the arrow in (A) indicates point of injection). Analysis 
of variance revealed that there were no group differences in the raw GABA levels of 
the baseline samples (F [1,13] = 0.014; not significant), nor was there a difference 
between the first and second baseline samples (F [1,13] = 4.42; not significant). 
Infusion of eticlopride into accumbens core significantly increased levels of 
extracellular GABA in ventral pallidum. Analysis of variance revealed a significant 
effect of drug treatment (F [1,13] = 8.02; p < 0.05) and a significant treatment by 
sample interaction (F [6,78] = 3.54; p < 0.05). Non-orthogonal planned 
comparisons revealed that the eticlopride-treated group had significantly elevated 
VP GABA levels at the first and second postinjection samples (*p < 0.05). 
Furthermore, orthogonal ana lysis of trends across all seven samples for the 
percentage baseline data demonstrated a significant sample X treatment 
interaction for the quadratic trend (F [1,13] = 7.20; p < 0.05), indicating that ventral 
pallidal GABA levels in the eticlopride-treated group showed an increase followed 
by a decrease, whereas GABA levels for the vehicle group did not.
VP: Ventral pallidum.
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motor function in depressed patients and those 
with parkinsonism [142], and observed that 
motor slowing in depression is behaviorally 
quite similar to parkinsonian bradykinesia. 
They suggested that motor slowing in depres-
sion and parkinsonism could result from com-
mon underlying mechanisms. Psychomotor 
slowing is often observed during withdrawal 
from stimulant addiction, and it was the psy-
chiatric symptom most strongly associated with 
reduced levels of striatal DA transporter density 
in a PET study of methamphetamine abusers in 
withdrawal [143]. Furthermore, there are individ-
uals who have a severe motivational disturbance 
that has been labeled as anergia, or apathy, yet 
these individuals do not meet the diagnostic 
criteria for depression [148,149]. Energy-related 
symptoms in these people can be ameliorated 
with the DA agonist bromocriptine, and it has 
been suggested that DA is involved in this type 
of syndrome [148,149]. The DA uptake inhibi-
tor buproprion improved apathy symptoms in 
patients with organic brain disease [150]. Loss 
of drive or motivation and a lack of initiation 
of spontaneous activities was reported to be 
improved by administration of the antiparkin-
sonian DA agonist bromocriptine in patients 
who had either traumatic brain injury or sub-
arachnoid hemorrhage [151]. Another disorder 
associated with energy-related symptoms such 
as fatigue is multiple sclerosis [152,153]. Fatigue 
in multiple sclerosis has been described as “a 
feeling of physical tiredness and lack of energy 
distinct from sadness or weakness” [154]. Basal 
ganglia mechanisms have been implicated in 
multiple sclerosis-related fatigue [155], and drugs 
that act on DA such as pemoline and bupro-
prion have been used to treat this symptom 
[153,156]. Furthermore, HIV patients can also 
show apathy, and a recent morphometric study 
demonstrated that this apathy in HIV patients 
is accompanied by reductions in nucleus 
accumbens volume [157].
It is evident from the review of the animal 
research provided above that adenosine A2A 
receptor antagonists could represent novel 
therapeutic targets for the treatment of energy-
related symptoms in humans. At present, a 
number of these drugs are being developed as 
treatments for idiopathic Parkinson’s disease. 
As fatigue is often a feature of Parkinson’s dis-
ease [152], the next generation of studies could 
provide a unique opportunity to investigate the 
ability of adenosine A2A antagonists to improve 
energy-related symptoms. Additional research 
should also focus on the effects of adenosine 
A2A antagonists on psychomotor slowing and 
fatigue in patients treated with antipsychotic 
drugs, as well as people with multiple sclero-
sis, depression or other disorders. For all these 
studies, it will be useful to place emphasis on 
the continued development of both self-report 
and behavioral assessment tools, in order to 
characterize the symptoms and measure their 
responsiveness to treatment. 
Conclusion
In summary, there are multiple components of 
the forebrain circuitry regulating behavioral 
activation and effort-related processes. One 
nodal point in this circuitry is the DA inner-
vation of nucleus accumbens [11,13,77,85,158]. Low 
systemic doses of DA antagonists, local injec-
tions of DA antagonists into nucleus accumbens 
and neurotoxic depletion of accumbens DA, 
all produce a condition that results in lower 
behavioral activation and decreased output of 
food-motivated instrumental behavior, par-
ticularly when the instrumental response has 
a substantial work requirement. These actions 
occur despite the fact that these manipula-
tions have little or no effect on appetite for 
food, or primary or unconditioned food moti-
vation [13]. In addition, DA manipulations 
produce a bi directional modulation of effort-
related choice behavior. Decreasing accumbens 
DA transmission biases animals towards 
lower-effort alternatives, although these ani-
mals remain directed towards the acquisition 
and consumption of the primary motivational 
stimulus [11,13,158]. By contrast, increasing DA 
transmission has been demonstrated to increase 
selection of high-effort alternatives [79,87]. 
Along with nucleus accumbens, additional 
components of this circuitry in animals and 
humans include prefrontal/anterior cingulate 
cortex, basolateral amygdala and ventral pal-
lidum [93,131,159–161]. Furthermore, DA inter-
acts with the purine neuromodulator adeno-
sine, particularly in the nucleus accumbens, 
to regulate effort-related functions [13,77,85,158]. 
Adenosine A2A agonists injected into nucleus 
accumbens can mimic the effects of DA 
depletion or antagonism, while adenosine A2A 
antagonists can attenuate the effort-related 
b ehavioral effects of DA D2 antagonists.
As well as providing basic science informa-
tion regarding a fundamental aspect of normal 
motivation, research in this area can also yield 
insights into pathological aspects of motiva-
tion in humans [134]. Symptoms such as anergia, 
psycho motor slowing, apathy and fatigue, which 
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represent conditions in which there are abnor-
mally low levels of behavioral activation, are 
frequently observed in patients with depression 
and other psychiatric and neurological disorders. 
Subjectively, patients with these symptoms report 
a lack of energy, and research indicates that there 
are also profound behavioral manifestations that 
can be maladaptive and debilitating. The severity 
of these psychomotor or energy-related symptoms 
is related to problems with social function and 
employment, as well as treatment outcomes [162]. 
Importantly, an examination of the basic sci-
ence and clinical literature indicates that there 
are noteworthy similarities between the brain 
circuitry and neuro chemical systems that have 
been implicated in effort-related processes in ani-
mals and those involved in pathological aspects 
of behavioral activation in humans [11,134]. These 
observations suggest that basic research on ani-
mals can yield critical insights into the neural 
underpinnings of energy-related dysfunctions in 
humans, and that such research could ultimately 
lead to novel treatments for these disorders. For 
example, it is possible that adenosine A2A receptor 
antagonists that are currently being developed 
for their antiparkinsonian effects could be ben-
eficial for treating energy-related symptoms in 
humans [11,119,163].
Future perspective
As previously described, in most animal studies 
adenosine A2A receptor antagonists appear to be 
more effective at reversing the effects of D2 antago-
nists than they are at reversing the effects of D1 
antagonists. This will have to be investigated more 
thoroughly in humans, but it could have implica-
tions for the development of these compounds as 
clinical tools. As DA depletions result in a lack 
of D1 as well as D2 receptor stimulation, it may 
be that adenosine A2A antagonists will have lim-
ited efficacy in treating patients with idiopathic 
Parkinson’s disease. As previously described, ade-
nosine A2A receptor antagonists appear to have 
more direct effects on the medium spiny cells 
that also contain D2 receptors, but their ability to 
interact with so-called direct pathway neurons, 
which are more likely to contain D1 receptors, may 
be somewhat limited. For these reasons, it would 
be useful to consider combination treatments that 
include drugs that act on other parts of the striatal 
circuitry, which are less influenced by the effect of 
adenosine A2A receptor blockade; such treatments 
could include D1 agonists or muscarinic M4 antag-
onists [131]. This strategy could yield benefits for 
the treatment of motor symptoms of Parkinson’s 
disease, but could also be advantageous for the 
treatment of energy-related symptoms as well.
Executive summary
Diverse aspects of motivation
!"Directional aspects: behavior is directed towards or away from stimuli.
!"Activational aspects: motivated behavior is characterized by a high degree of vigor, persistence and effort.
Dopaminergic involvement in behavioral activation & effort
!"Low doses of dopamine (DA) antagonists, as well as accumbens DA depletions or antagonism, do not impair appetite for food or 
primary food motivation. It is overly simplistic to label nucleus accumbens DA as a ‘reward’ or ‘pleasure’ system.
!"Interference with DA transmission impairs activational aspects of motivation, making it less likely that animals will work for stimuli such 
as food.
!"Interference with accumbens DA transmission affects effort-related decision making, biasing animals towards low-effort alternatives.
Dopamine & adenosine interact in the regulation of effort-related processes
!"Adenosine A2A agonists, when injected into the accumbens, produce effects that resemble those of accumbens DA depletion 
or antagonism.
!"Adenosine A2A antagonists reverse the effort-related effects of DA antagonists, while A1 antagonists are relatively ineffective. 
!"There is a very specific interaction between DA D2 and adenosine A2A receptors, which is probably related to the colocalization of these 
receptors in the same population of medium spiny neurons.
!"The nucleus accumbens is an important locus at which DA D2 and adenosine A2A receptors interact in order to regulate 
effort-related processes. 
!"Effort-related output from the nucleus accumbens to related forebrain circuits appears to be conveyed by the GABAergic ventral 
striatopallidal pathway.
!"The broader forebrain circuitry involved in effort-related processes includes the anterior cingulate cortex and basolateral amygdala.
Clinical implications
!"Animal research on behavioral activation and effort-related decision making may provide insights into the neurochemistry and 
pharmacology of effort- or energy-related symptoms, such as psychomotor slowing, anergia, apathy and fatigue, which are seen in 
various psychiatric and neurological disorders.
Future perspective
!"Adenosine A2A receptor antagonists may be useful for the treatment of energy-related symptoms in humans.
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In view of the apparent specificity of the 
interaction between DA D2 and adenosine A2A 
receptors, another potential use for adeno sine 
A2A antagonists is the treatment of the behav-
ioral side effects, both motor and motivational, 
that are produced by antipsychotic drugs 
[115,116,119]. The vast majority of antipsychotic 
drugs are D2 antagonists, and the therapeutic 
utility of these compounds is directly related to 
actions on the D2 receptor family, as opposed 
to the D1 receptor family. Thus, in view of the 
consistent findings in the animal literature that 
demonstrates that adenosine A2A antagonists 
readily reverse the actions of D2 antagonists, 
clinical studies assessing this effect need to 
be conducted. Of course, in order to be clini-
cally useful, the question of whether or not 
adenosine A2A antagonists also reverse the 
therapeutic effect of antipsychotics needs to 
be addressed. Such research would not only 
be necessary from a practical standpoint, but 
it would also have an added benefit, in that it 
would test one of the recent theories of antipsy-
chotic action. Although many researchers have 
maintained that the therapeutic and behavioral 
side effects of antipsychotic drugs result from 
actions on distinct mechanisms, it has recently 
been suggested that the therapeutic effect of D2 
antagonists is a result of actions on subcorti-
cal dopaminergic mechanisms, including those 
in nucleus accumbens, which are involved in 
aspects of motivation such as motivational 
salience and arousal [164]. Thus, research in 
this area could afford a valuable opportunity 
that would have both clinical and theoretical 
implications. If adenosine A2A antagonists can 
reverse the motivational effects of D2 antago-
nists, but leave the therapeutic antipsychotic 
effect intact, then it would indicate that these 
effects are actually a result of actions on dis-
tinct and dissociable mechanisms. Moreover, 
such a finding would promote the develop-
ment of novel clinical tools for the treatment 
of pathological aspects of motivation.
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